Rocket Pharmaceuticals, Inc.
RP-A701
BAG3-associated dilated cardiomyopathy (BAG3-DCM)
Countdown
56days
Phase 1 readout · ~ Aug 31, 2026 estimated
What's at stake
Phase 1 trial results for RP-A701 in BAG3-associated dilated cardiomyopathy (BAG3-DCM) are due ~ Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Rocket expects to dose the first BAG3-DCM patient mid-2026.”